CoQ10 in Huntington’s study
This article was originally published in The Tan Sheet
Executive Summary
The effect of coenzyme Q10 on cognitive function in Huntington's disease patients will be tested in a phase III clinical trial by the Huntington Study Group, according to a June 2 release. The five-year study will measure the maximum effective dosage of CoQ10 for treating Huntington's, a genetic, progressive brain disorder with no known cure or proven drug therapy. Pasadena, Texas-based Kaneka Nutrients will supply the supplement for the trial. In addition to its documented neurological benefits, CoQ10 has cardio health advantages pharmaceutical developers are attempting to harness (1"The Tan Sheet" June 2, 2008, p. 8)...
You may also be interested in...
Dietary Supplements Blossom As Revenue Growth Ingredients For Big Pharma
Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.